Key result
Higher baseline RDW is linked to ~8% greater major cardiovascular events risk per percent increase after recent ACS.
Why the study?
Elevated RDW is associated with increased MACE and death in cardiovascular disease, but whether RDW independently predicts risk after ACS, influences MACE reduction with alirocumab, or is affected by alirocumab remained to be determined.
Does elevated red blood cell distribution width (RDW) predict major adverse cardiovascular events (MACE) and death in patients with recent acute coronary syndrome (ACS)?
RCT (n=18,924)
Does elevated red blood cell distribution width (RDW) predict major adverse cardiovascular events (MACE) and death in patients with recent acute coronary syndrome (ACS)?
Answers are grounded in this paper and cite their sources.
Red blood cell distribution width (RDW) is an independent predictor of MACE and death after recent ACS, offering a zero-cost prognostic biomarker.
•RDW independently associates with risk of MACE and death in patients with recent ACS.•RDW adds to information provided by other risk factors and biomarkers, such as hs-CRP.•RDW is an existing component of the complete blood count.•As such, RDW provides useful predictive information after ACS at no incremental cost. Elevated red blood cell distribution width (RDW) is associated with increased risk for major adverse cardiovascular events (MACE) and death in patients with cardiovascular disease. The ODYSSEY OUTCOMES trial compared alirocumab with placebo in 18,924 patients with recent acute coronary syndrome (ACS) and elevated atherogenic lipoproteins despite optimized statin treatment. This post hoc analysis determined whether RDW independently predicts risk of MACE and death in patients after recent ACS, whether RDW influences MACE reduction with alirocumab, and whether alirocumab treatment affects RDW. Associations of baseline RDW with risk of MACE and death were analyzed in the placebo group in adjusted proportional hazards models. Interactions of RDW and treatment on the risk of MACE and death were evaluated. An increasing quartile of RDW was associated with characteristics that predicted risk of MACE and death including age, hypertension, diabetes, atherosclerotic conditions and events, revascularizations, low-density lipoprotein cholesterol, and high-sensitivity C-reactive protein. After adjusting for baseline characteristics associated with the risk of MACE or death, baseline RDW remained independently associated with the risk of MACE and death in the placebo group (hazard ratios [95% confidence intervals] 1.08 [1.02–1.15] and 1.13 [1.03–1.24] per 1% increase of RDW, respectively, both p <0.001). There was no interaction of RDW and treatment on MACE or death, nor did alirocumab affect RDW. RDW was associated with an increased risk of MACE and death, independent of established risk factors. Elevated red blood cell distribution width (RDW) is associated with increased risk for major adverse cardiovascular events (MACE) and death in patients with cardiovascular disease. The ODYSSEY OUTCOMES trial compared alirocumab with placebo in 18,924 patients with recent acute coronary syndrome (ACS) and elevated atherogenic lipoproteins despite optimized statin treatment. This post hoc analysis determined whether RDW independently predicts risk of MACE and death in patients after recent ACS, whether RDW influences MACE reduction with alirocumab, and whether alirocumab treatment affects RDW. Associations of baseline RDW with risk of MACE and death were analyzed in the placebo group in adjusted proportional hazards models. Interactions of RDW and treatment on the risk of MACE and death were evaluated. An increasing quartile of RDW was associated with characteristics that predicted risk of MACE and death including age, hypertension, diabetes, atherosclerotic conditions and events, revascularizations, low-density lipoprotein cholesterol, and high-sensitivity C-reactive protein. After adjusting for baseline characteristics associated with the risk of MACE or death, baseline RDW remained independently associated with the risk of MACE and death in the placebo group (hazard ratios [95% confidence intervals] 1.08 [1.02–1.15] and 1.13 [1.03–1.24] per 1% increase of RDW, respectively, both p <0.001). There was no interaction of RDW and treatment on MACE or death, nor did alirocumab affect RDW. RDW was associated with an increased risk of MACE and death, independent of established risk factors.
No takes yet. Share an insight, caveat, or question.
Moriarty et al. (2022) conducted an RCT in Recent acute coronary syndrome (ACS) and elevated atherogenic lipoproteins (n=18,924). Alirocumab vs. Placebo was evaluated on MACE and death (HR 1.08 (MACE), HR 1.13 (death), 95% CI 1.02-1.15 (MACE), 1.03-1.24 (death), p=<0.001). Baseline red blood cell distribution width was independently associated with increased risk of major cardiovascular events and death per 1% increase after recent ACS.
Synapse has enriched 10 related papers. Consider them for comparative context: